{"task_id":"T1R-01","category":"Tier 1 Retrieval","user_query":"At what age should female ATM heterozygotes generally begin breast-cancer surveillance with MRI according to current recommendations?","gold_standard_output":"The ACMG 2024 ATM practice resource states that most ATM heterozygotes meet criteria for *enhanced* breast surveillance and, depending on national guidelines, breast MRI is typically initiated between ages **30 and 40 years** (often age 30 in jurisdictions that adopt the lower threshold)."}
{"task_id":"T1R-02","category":"Tier 1 Retrieval","user_query":"List three cancers for which ATM heterozygotes have a clearly documented increased risk and provide the approximate odds ratio or relative-risk range given in the guideline.","gold_standard_output":"According to the 2024 ACMG ATM guideline: ① **Female breast cancer** (OR ≈ 1.8 – 2.3); ② **Pancreatic cancer** (RR ≈ 4.2 – 6.5 in population studies); ③ **Prostate cancer** (OR ≈ 1.9 – 2.6, particularly aggressive or early-onset disease)."}
{"task_id":"T1R-03","category":"Tier 1 Retrieval","user_query":"What stance does the ACMG practice resource take on using prophylactic mastectomy in unaffected ATM heterozygous women?","gold_standard_output":"The guideline advises that *routine* bilateral risk-reducing mastectomy is **not recommended** for unaffected ATM heterozygotes; it may be considered only after individualized risk modeling (eg, CanRisk) and shared decision-making if lifetime risk exceeds local thresholds."}
{"task_id":"T1R-04","category":"Tier 1 Retrieval","user_query":"According to the ACMG MPS II Delphi practice resource, when should enzyme-replacement therapy be started in a child aged six with severe Hunter syndrome who is already showing neurologic decline?","gold_standard_output":"The Delphi consensus (Phase 2 survey statements 3B & 5B) concluded that ERT *should* be started in **any child with severe MPS II (age 6–10 years) who is demonstrating neurologic decline**, primarily to address somatic disease even though CNS benefit is not expected."}
{"task_id":"T1R-05","category":"Tier 1 Retrieval","user_query":"Name two validated clinical tests the MPS II guideline recommends for routine functional follow-up and specify when they should *not* be used.","gold_standard_output":"The ACMG document supports ① the **3-minute stair-climb test (3MSCT)** and ② the **6-minute walk test (6MWT)** for functional follow-up, but notes that these should *not* be used in patients who cannot complete them reliably (eg, very young children, severe cognitive impairment), in which case alternate assessments are chosen."}
{"task_id":"T1R-06","category":"Tier 1 Retrieval","user_query":"Summarize the Boxed Warning attached to velmanase alfa therapy.","gold_standard_output":"The 2024 ACMG Therapeutics Bulletin for velmanase alfa notes an FDA boxed warning for **serious hypersensitivity reactions, including anaphylaxis**; clinicians must have resuscitation equipment ready and consider pre-medication or infusion-rate adjustments."}
{"task_id":"T1R-07","category":"Tier 1 Retrieval","user_query":"After how many months of velmanase-alfa exposure were statistically significant improvements in 3-minute stair-climb and 6-minute walk seen in pooled trials?","gold_standard_output":"Integrated Phase I/II + III analyses (mean exposure **29.3 months**) demonstrated significant gains in both 3MSCT and 6MWT versus baseline."}
{"task_id":"T1R-08","category":"Tier 1 Retrieval","user_query":"State the ACMG PAH guideline’s recommended therapeutic blood-phenylalanine range for *all* ages.","gold_standard_output":"The 2014 ACMG PAH guideline recommends maintaining blood Phe **120 – 360 µmol/L** lifelong for infants, children, adolescents, and adults."}
{"task_id":"T1R-09","category":"Tier 1 Retrieval","user_query":"What does the ACMG PAH guideline advise regarding sapropterin use during pregnancy?","gold_standard_output":"It classifies sapropterin as FDA pregnancy **Category C** and allows use when benefits (lowering maternal Phe to <360 µmol/L) outweigh potential risks; ideally responsiveness is confirmed *before* conception."}
{"task_id":"T1R-10","category":"Tier 1 Retrieval","user_query":"List three neurocognitive or psychiatric issues highlighted in the ACMG PAH guideline that may emerge despite early treatment.","gold_standard_output":"Documented late sequelae include (1) **executive-function deficits**, (2) **depression/anxiety**, and (3) **externalizing behavior/attention-deficit symptoms** that correlate with lifelong Phe control."}
{"task_id":"T2R-01","category":"Tier 2 Retrieval","user_query":"Which gene is associated with classic ataxia-telangiectasia and what is its typical inheritance pattern?","gold_standard_output":"GeneReviews (A-T chapter) states that classic A-T results from biallelic pathogenic variants in **ATM** and follows **autosomal-recessive** inheritance."}
{"task_id":"T2R-02","category":"Tier 2 Retrieval","user_query":"Name two hallmark neurologic features of ataxia-telangiectasia that usually appear in early childhood.","gold_standard_output":"The chapter emphasizes (1) **progressive cerebellar ataxia** with onset in infancy/toddler years and (2) **oculomotor apraxia** leading to head thrusting during saccades."}
{"task_id":"T2R-03","category":"Tier 2 Retrieval","user_query":"What major immunologic abnormality predisposes individuals with A-T to sinopulmonary infections?","gold_standard_output":"GeneReviews describes **IgA deficiency (often with low IgG2/IgG4)** as a common humoral-immune deficit underlying recurrent sinopulmonary infections."}
{"task_id":"T2R-04","category":"Tier 2 Retrieval","user_query":"Identify the enzymatic defect and gene in Hunter syndrome.","gold_standard_output":"The GeneReviews Hunter syndrome entry states the disorder is caused by pathogenic variants in **IDS** encoding **iduronate-2-sulfatase**, leading to dermatan- and heparan-sulfate accumulation."}
{"task_id":"T2R-05","category":"Tier 2 Retrieval","user_query":"Which inheritance pattern characterizes Hunter syndrome and how does that impact carrier risk in daughters of affected males?","gold_standard_output":"Hunter syndrome is **X-linked recessive**; therefore, *all* daughters of an affected male are **obligate heterozygous carriers**."}
{"task_id":"T2R-06","category":"Tier 2 Retrieval","user_query":"List two early somatic signs in infants with Hunter syndrome noted in GeneReviews.","gold_standard_output":"Common early somatic manifestations include (1) **inguinal or umbilical hernias** and (2) **recurrent otitis media with conductive hearing loss**."}
{"task_id":"T2R-07","category":"Tier 2 Retrieval","user_query":"According to GeneReviews, which laboratory screening test detects excessive mannose-rich oligosaccharides in alpha-mannosidosis?","gold_standard_output":"**Urine oligosaccharide chromatography (TLC or HPLC)** revealing a characteristic mannose-rich pattern is cited as the frontline screening test."}
{"task_id":"T2R-08","category":"Tier 2 Retrieval","user_query":"What two broad clinical subtypes of alpha-mannosidosis are described and how do they differ in onset?","gold_standard_output":"GeneReviews delineates (a) **Type I (mild/moderate, childhood-onset)** with hearing loss and gradual motor decline, and (b) **Type II (severe, infantile-onset)** with rapid progression and pronounced skeletal/cognitive issues. (The neonatal lethal form is occasionally considered Type III.)"}
{"task_id":"T2R-09","category":"Tier 2 Retrieval","user_query":"Which dietary treatment remains the primary therapy for phenylalanine hydroxylase deficiency and what blood-Phe target does GeneReviews recommend?","gold_standard_output":"GeneReviews PAH chapter affirms **lifelong low-phenylalanine diet supplemented by Phe-free medical foods** as first-line therapy, aiming to keep Phe **120–360 µmol/L** throughout life."}
{"task_id":"T2R-10","category":"Tier 2 Retrieval","user_query":"State one maternal phenylketonuria (MPKU) risk to the fetus if maternal Phe exceeds 600 µmol/L in early gestation.","gold_standard_output":"GeneReviews cautions that maternal Phe > 600 µmol/L before 8 weeks gestation markedly increases the risk for **congenital heart defects** in the fetus."}
{"task_id":"MS-1","category":"Multi-Source Synthesis","user_query":"For Hunter syndrome, when should enzyme-replacement therapy be started, and under what circumstances might it be stopped?","gold_standard_output":"Must (i) state that idursulfase (ERT) is generally initiated in infants/children once diagnosis is confirmed, including presymptomatic infants predicted to develop severe disease; (ii) explain that ERT may be withheld or deferred in attenuated infants who are entirely asymptomatic; (iii) list discontinuation circumstances endorsed by ACMG: uncontrolled anaphylaxis or documented lack of clinical/biochemical response after a ≥12- to 18-month trial despite good adherence; (iv) add that GeneReviews similarly recommends continuing ERT lifelong unless life-threatening infusion reactions cannot be mitigated or the family chooses palliative care; (v) explicitly mention that stopping solely because of neurologic progression is **not** advised; (vi) cite that re-challenging after desensitization may be attempted before permanent cessation."}
{"task_id":"MS-2","category":"Multi-Source Synthesis","user_query":"List the routine surveillance evaluations recommended for individuals with Hunter syndrome.","gold_standard_output":"Must combine: (1) ACMG surveillance items – annual skeletal assessment (pain/range-of-motion), audiology + ENT exams, neuropsychological testing, ophthalmology, pulmonary function (when reliable), liver and spleen size by physical exam ± imaging, urine GAGs, antibody testing if infusion reactions; (2) GeneReviews surveillance – echocardiography every 1-2 years, polysomnography for sleep-apnea risk, brain/cord MRI if neurologic decline, hearing aids/PE-tube review, endocrine growth monitoring; (3) clearly note frequency suggestions where provided (e.g., audiology 6–12 mo, echo 1–2 yr, neuropsych yearly); (4) emphasize multidisciplinary coordination across ENT, cardiology, pulmonology, orthopedics, neurology, rehab, genetics."}
{"task_id":"MS-3","category":"Multi-Source Synthesis","user_query":"Explain how genotype influences phenotype severity in Hunter syndrome and how that affects treatment decisions.","gold_standard_output":"Must say: (i) Pathogenic IDS variants causing absent or <1% iduronate-2-sulfatase activity predict the severe neuronopathic form with rapid progression; missense or splice variants retaining partial activity correlate with attenuated phenotypes. (ii) ACMG notes that because severity lies on a continuum and is hard to predict at birth, ERT is recommended for all molecularly confirmed infants unless clearly mild and asymptomatic. (iii) GeneReviews provides examples of nonsense/frameshift variants linked to early neurologic decline versus later-onset missense variants. (iv) For severe-predicting genotypes, early ERT plus consideration of intrathecal trials and experimental therapies is advised; for attenuated genotypes, focus is on somatic benefit, shared decision-making about timing, and monitoring rather than prophylactic risk-reducing surgery. (v) Conclude that genotype guides counseling but does **not** currently alter ERT dosing, only urgency of initiation and expectation setting."}
{"task_id":"MS-4","category":"Multi-Source Synthesis","user_query":"Summarize the core long-term management plan for classical phenylketonuria, including diet, medication options, and monitoring.","gold_standard_output":"Must integrate: (1) ACMG 2014 guideline – life-long treatment; maintain blood Phe 120-360 µmol/L; primary therapy is low-Phe diet with Phe-free medical foods + low-protein modified foods; sapropterin 5-20 mg/kg daily for responders (≈25-50% of patients) to raise Phe tolerance; LNAA reserved for older adolescents/adults and **not** used in pregnancy; weekly Phe checks infancy, bi-weekly/monthly childhood, monthly adulthood; monitor full amino-acids, vitamins/minerals, essential fatty acids. (2) GeneReviews – same Phe targets; details on calculating Phe allowance via exchange lists; stresses annual multidisciplinary visits; describes criteria and protocol for sapropterin responsiveness testing; notes potential future PEG-PAL therapy under investigation. (3) Output must specify that treatment decisions are individualized but goal is neurocognitive protection, and that inadequate control relates to executive-function deficits and psychiatric symptoms."}
{"task_id":"MS-5","category":"Multi-Source Synthesis","user_query":"Describe how hyperphenylalaninemia affects pregnancy and what metabolic targets are recommended for maternal PKU management.","gold_standard_output":"Must state: (i) Both sources agree uncontrolled maternal Phe (>360 µmol/L) early in gestation leads to microcephaly, congenital heart defects, growth retardation, and intellectual disability (maternal PKU syndrome). (ii) ACMG guideline specifies target maternal Phe 60-360 µmol/L **before conception** and throughout pregnancy, with stricter <240 µmol/L used by many programs; weekly or more frequent Phe monitoring; sapropterin (class C) can be continued if benefits outweigh risks; LNAA contraindicated as sole therapy. (iii) GeneReviews echoes goals, emphasizing diet initiation ideally 3 months pre-conception; describes fetal heart forming by 8-10 weeks—critical window; notes breast-feeding is permissible on Phe-restricted diet postpartum. (iv) Must mention need for prenatal vitamins without excess vitamin A and monitoring B12, weight gain, fetal ultrasound + echo."}
{"task_id":"MS-6","category":"Multi-Source Synthesis","user_query":"How is phenylketonuria detected on newborn screening and distinguished from tetrahydrobiopterin defects?","gold_standard_output":"Must include: (1) ACMG details – tandem mass-spectrometry detects elevated whole-blood Phe; typical laboratory cut-off ~130 µmol/L but varies 65–234; Phe/Tyr ratio >3 flagged; confirmatory plasma amino acids plus pterin analysis (urine or dried-blood) and DHPR activity on filter paper to rule out BH4 disorders; molecular PAH sequencing recommended. (2) GeneReviews complements – notes false positives from liver disease or parenteral nutrition; describes GTPCH, PTPS, DHPR, PCD deficiencies causing secondary PKU; outlines neopterin/biopterin profiling and load test; discusses value of genotype for prognosis. (3) Output must clarify that PAH enzyme assay is only in liver/kidney so not used diagnostically; and that rapid treatment initiation within first week is goal."}
{"task_id":"MS-7","category":"Multi-Source Synthesis","user_query":"What is velmanase alfa, and which clinical outcomes has it improved for alpha-mannosidosis patients?","gold_standard_output":"Must state: (i) Velmanase alfa-tycv is recombinant human alpha-mannosidase with mannose-6-phosphate; FDA approved 2024 for non-CNS manifestations in adults & children; weekly IV infusion. (ii) ACMG bulletin reports phase III trial of 25 pts ages 5–35: significant serum oligosaccharide clearance; trends in 3-min stair climb (3MSCT), 6-min walk (6MWT), FVC; pediatric subgroup most benefit; integrated long-term data (mean 29 mo) show sustained improvement in 3MSCT, 6MWT, FVC. (iii) GeneReviews describes natural history—progressive hearing loss, skeletal changes, ataxia—and notes velmanase alfa shown to reduce infections, improve endurance, and lower serum/urinary oligosaccharides in trials; CNS disease unaffected. (iv) Must mention boxed warning for anaphylaxis, infusion reactions in ~36–58% pts, and absence of pregnancy data."}
{"task_id":"MS-8","category":"Multi-Source Synthesis","user_query":"Compare bone-marrow transplantation with velmanase alfa therapy for alpha-mannosidosis.","gold_standard_output":"Must combine: (1) GeneReviews – BMT/HCT can partially stabilize neurocognitive course and improve hearing, immune function; benefits greatest if <10 yrs and before severe CNS damage; significant morbidity/mortality from conditioning and graft-versus-host. (2) ACMG bulletin – velmanase alfa treats **non-CNS** symptoms; clinical trials show gains in endurance and reduced oligosaccharide burden; does not cross blood–brain barrier, so no proven neurologic benefit; lower risk profile than BMT but hypersensitivity common. (3) Synthesis must contrast mechanisms (enzyme replacement vs donor enzyme-producing leukocytes), scope of benefit (somatic vs somatic+partial CNS), and risk levels; should conclude that therapy choice depends on age, CNS status, and risk tolerance."}
{"task_id":"MS-9","category":"Multi-Source Synthesis","user_query":"Outline the recommended multidisciplinary surveillance for a child newly diagnosed with alpha-mannosidosis.","gold_standard_output":"Must state: (a) GeneReviews baseline & ongoing evaluations – audiology every 6–12 mo, skeletal exam with focus on pain/ROM, neuro-developmental and psych testing annually, ophthalmology for cataracts/strabismus, pulmonary function or polysomnography for OSA, immune work-up for infections, periodic brain MRI if ataxia progresses. (b) ACMG bulletin adds monitoring for serum oligosaccharides to gauge velmanase response, LFTs, infusion-related hypersensitivity vigilance, and quality-of-life assessments (3MSCT, 6MWT, FVC). (c) Must emphasize coordination among genetics, ENT, orthopedics, pulmonology, neurology, cardiology, PT/OT, immunology, and infusion nursing; frequencies where provided."}
{"task_id":"MS-10","category":"Multi-Source Synthesis","user_query":"Explain why large neutral amino acids are used in some adults with PKU and why they are not appropriate during pregnancy.","gold_standard_output":"Must integrate: (i) ACMG guideline – LNAA formulations compete with Phe for gut and BBB transport, lowering brain Phe; used in adolescents/adults who struggle with strict diet; typical dose 0.5–1 g/kg; not suitable as monotherapy in pregnancy because they do **not** reliably reduce maternal blood Phe to <360 µmol/L and fetal safety unknown. (ii) GeneReviews echoes LNAA benefit for executive-function symptoms in poorly controlled adults; notes they raise brain Tyr/Tryptophan for neurotransmitter synthesis; emphasizes contraindication in pregnancy and limited data in children. (iii) Output must also mention LNAA do not replace medical foods’ vitamin/mineral content, so supplementation still needed."}
{"task_id":"WF-1","category":"Wikipedia Fallback","user_query":"Could you outline the main clinical features of Marfan syndrome?","gold_standard_output":"Assistant should indicate that the requested syndrome is not covered in the provided ACMG or GeneReviews PDFs and therefore must consult a trusted open resource (e.g., Wikipedia) to obtain its cardiovascular, ocular, and skeletal features."}
{"task_id":"WF-2","category":"Wikipedia Fallback","user_query":"What is the typical inheritance pattern and gene for Pompe disease?","gold_standard_output":"Assistant must note the absence of Pompe disease data in supplied documents and must retrieve basic inheritance (autosomal-recessive) and GAA-gene information from an external reference such as Wikipedia or another reputable public source."}
{"task_id":"WF-3","category":"Wikipedia Fallback","user_query":"Summarize standard newborn-screening analytes measured for maple syrup urine disease.","gold_standard_output":"Assistant should state that maple syrup urine disease is not covered in the uploaded ACMG / GeneReviews PDFs and therefore needs to consult Wikipedia or an equivalent open source for screening details (elevated leucine/isoleucine, allo-isoleucine, etc.)."}
{"task_id":"WF-4","category":"Wikipedia Fallback","user_query":"Which metabolic block causes homocystinuria and what vitamin can sometimes help?","gold_standard_output":"Assistant must acknowledge that homocystinuria is not in the stored tier documents and thus must access an open reference (Wikipedia) to answer (CBS deficiency; pyridoxine responsiveness)."}
{"task_id":"WF-5","category":"Wikipedia Fallback","user_query":"List the diagnostic criteria for Williams syndrome.","gold_standard_output":"Assistant should note there is no Williams syndrome content in the provided corpus and must consult Wikipedia for cardiovascular, facial, and cognitive criteria."}
{"task_id":"WF-6","category":"Wikipedia Fallback","user_query":"Give a brief overview of the molecular mechanism behind sickle cell disease.","gold_standard_output":"Assistant should explicitly state the condition is outside the supplied PDFs and retrieve the HbS point-mutation details from Wikipedia or another open source."}
{"task_id":"WF-7","category":"Wikipedia Fallback","user_query":"What is the current FDA-approved therapy for spinal muscular atrophy type 1?","gold_standard_output":"Assistant must indicate no SMA data is present in the uploaded references and must look up up-to-date treatments (nusinersen, onasemnogene abeparvovec, risdiplam) via Wikipedia or equivalent."}
{"task_id":"WF-8","category":"Wikipedia Fallback","user_query":"Describe the distinctive craniofacial signs of Treacher Collins syndrome.","gold_standard_output":"Assistant should declare Treacher Collins is not covered in the tiered PDFs and consult Wikipedia for zygomatic arch hypoplasia, micrognathia, hearing loss, etc."}
{"task_id":"WF-9","category":"Wikipedia Fallback","user_query":"How common is cystic fibrosis in the general US population?","gold_standard_output":"Assistant must note cystic fibrosis epidemiology is not in the supplied documents and must obtain prevalence data from a public encyclopedia source such as Wikipedia."}
{"task_id":"WF-10","category":"Wikipedia Fallback","user_query":"Which chromosome carries the NF1 gene, and what is its protein product called?","gold_standard_output":"Assistant should state that neurofibromatosis type 1 genetics are absent from the provided PDFs and should retrieve from Wikipedia that NF1 is on chromosome 17 and encodes neurofibromin."}
{"task_id":"MI-1","category":"Missing Information Handling","user_query":"What is the recommended daily dosing protocol for enzyme replacement in Fabry disease?","gold_standard_output":"Assistant must respond that details for Fabry disease are **not available** in the provided documents, apologize for the limitation, and offer to look elsewhere or suggest consulting a specialist."}
{"task_id":"MI-2","category":"Missing Information Handling","user_query":"Could you compare the carrier-frequencies of Wilson disease across different ethnicities?","gold_standard_output":"Assistant should explain that the PDFs do not include Wilson disease data and therefore cannot provide an evidence-based ethnic comparison; it may offer to help locate authoritative external references."}
{"task_id":"MI-3","category":"Missing Information Handling","user_query":"Which locus heterogeneity has been described for Alport syndrome?","gold_standard_output":"Assistant must acknowledge absence of Alport syndrome in the tiered corpus, state that it lacks the requested locus heterogeneity details, and politely propose an external search."}
{"task_id":"MI-4","category":"Missing Information Handling","user_query":"What prenatal vitamin regimen is advised for women with glycogen-storage disease type III?","gold_standard_output":"Assistant must state the question falls outside the scope of uploaded PDFs and no internally stored evidence is available; it should recognize information gap and refrain from speculation."}
{"task_id":"MI-5","category":"Missing Information Handling","user_query":"List the consensus EEG findings characteristic of Dravet syndrome.","gold_standard_output":"Assistant should apologize that Dravet syndrome is not covered in supplied resources and hence cannot provide consensus EEG findings from those documents."}
{"task_id":"MI-6","category":"Missing Information Handling","user_query":"Provide the latest survival statistics for untreated Hurler syndrome.","gold_standard_output":"Assistant must indicate that the ACMG MPS II (Hunter) guideline does not include Hurler (MPS I) survival statistics; therefore, information is missing from the current corpus and cannot be quoted."}
{"task_id":"MI-7","category":"Missing Information Handling","user_query":"Give me detailed steps for performing CRISPR correction of a PAH gene mutation in vitro.","gold_standard_output":"Assistant must state that the provided ACMG/GeneReviews PAH documents do **not** include laboratory CRISPR protocols; acknowledge missing info and politely decline to fabricate methods."}
{"task_id":"MI-8","category":"Missing Information Handling","user_query":"What is the estimated cost of velmanase alfa treatment per year in the United States?","gold_standard_output":"Assistant should note that cost data are **not contained** in either the ACMG therapeutics bulletin or GeneReviews chapter, so it cannot provide a figure from the supplied evidence."}
{"task_id":"MI-9","category":"Missing Information Handling","user_query":"Detail all known IDS gene splice variants reported since 2022.","gold_standard_output":"Assistant must acknowledge that the Hunter-syndrome PDFs discuss missense/truncating vs splice variants generally but do **not** supply an exhaustive list through 2022; therefore, info is incomplete and cannot be provided from the given texts."}
{"task_id":"MI-10","category":"Missing Information Handling","user_query":"Enumerate the long-term renal outcomes in adults with classical PKU.","gold_standard_output":"Assistant should respond that neither the ACMG PKU guideline nor the GeneReviews chapter report renal outcome data; hence, it cannot supply an evidence-based answer from provided documents."}